Thymosin Alpha-1 vs Thymogen
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ta1, Zadaxin
Thymosin alpha-1 (sold as Zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. Unlike most peptides in this space, it is a real, approved drug in over 35 countries for chronic hepatitis B and as an immune booster, though it has never been approved by the FDA in the United States. It has one of the larger human evidence bases of any peptide here, with trials in tens of thousands of patients.
Also: EW Dipeptide, Glu-Trp
Thymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Thymosin Alpha-1 | Thymogen |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin alpha-1 works as an immune modulator rather than a stimulant, meaning it tries to rebalance the immune system rather than simply rev it up. It signals through toll-like receptors, particularly TLR9 and TLR2, on dendritic cells, which are the immune system's messengers. That signaling pushes naive T cells toward a Th1 (pathogen-fighting) profile, boosts natural killer cell activity, and improves antibody responses. At the same time it can promote regulatory T cells via the IDO pathway, which is why it is described as restoring balance: it can both wake up a sluggish immune response and dampen a dangerously overactive one. | Thymogen is meant to mimic what thymus-derived peptides do to the immune system. In experiments it has been reported to push T-cell differentiation, improve T-cell recognition of peptide-MHC complexes, shift the balance of intracellular cyclic nucleotides, and ramp up neutrophil chemotaxis and phagocytosis. In plain terms, it is proposed to wake up parts of the immune defense, especially in states where immunity is run down. Like other Khavinson peptides, it has also been described as influencing gene expression at the level of DNA, though the immunomodulatory effects are the better-documented part of its story. The exact molecular trigger that starts these effects is not fully pinned down. |
| Common Dosing | 1.6 mg twice weekly 2-3x weekly | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | Subcutaneous injection | Oral capsules, also available as nasal spray in some regions |
| Typical Duration | 6-12 months for hepatitis | 30-day courses with 2-3 month breaks |
| Best Time to Take | Morning | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with serious human trial data, but the results are mixed and worth reading honestly. Thymosin alpha-1 is approved and widely used for chronic hepatitis B, often alongside interferon, and decades of use give it a strong safety record across more than 30 trials and over 11,000 subjects. The standout area is sepsis, and the story there is a cautionary tale: the earlier ETASS trial (Critical Care, 2013) hinted at lower 28-day mortality (26 percent versus 35 percent), but the much larger, better-designed TESTS phase 3 trial (BMJ, 2025, 1,106 patients, double-blind and placebo-controlled) found no mortality benefit at all (23.4 versus 24.1 percent). It has also been studied as an add-on in certain cancers and in vaccine response, with weaker evidence. The honest summary: real drug, good safety, proven in hepatitis B, but several of its most-hyped uses did not survive a rigorous trial. | The most-cited international study is Anisimov and colleagues in Biogerontology (2000), where the dipeptide was given to rats and was associated with a longer maximum lifespan and markedly lower tumor incidence, including a roughly 3.4-fold drop in blood cancers versus controls. That is an animal study, not a human trial. A large body of supporting clinical and laboratory data exists, but it is overwhelmingly Russian-language, older, and produced by groups connected to the original developers, with little independent Western replication. There are no modern randomized controlled trials by outside labs confirming the immune or anti-aging claims to current evidence standards. So the fair summary is: decades of use and a real animal signal for immune and anti-tumor effects, but the high-quality, independently verified human evidence that Western medicine would want is simply not there. |
Frequently Asked Questions: Thymosin Alpha-1 vs Thymogen
What is the difference between Thymosin Alpha-1 and Thymogen?
Thymosin Alpha-1 is a immune peptide that thymosin alpha-1 (sold as zadaxin, generic name thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your immune system. unlike most peptides in this space, it is a real, approved drug in over 35 countries for chronic hepatitis b and as an immune booster, though it has never been approved by the fda in the united states. it has one of the larger human evidence bases of any peptide here, with trials in tens of thousands of patients. Thymogen is a immune peptide that thymogen is the brand name for l-glu-l-trp (glutamyl-tryptophan, the dipeptide ew), an immune-modulating peptide isolated from the calf thymus extract thymalin. it is the smallest active piece of that thymic complex and is studied for boosting t-cell activity and immune function. it has been used clinically in russia since 1990 but has never been evaluated or approved by any western regulator, and rigorous independent trials are lacking. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymosin Alpha-1 or Thymogen?
Neither is universally "better" - the choice depends on your specific goals. Thymosin Alpha-1 is typically used for immune purposes, while Thymogen is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymosin Alpha-1 and Thymogen be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Alpha-1 and Thymogen together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.